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Objective: To determine the in vitro antimicrobial activity, postantibiotic effect (PAE) and human monocyte activity of 
grepafloxacin compared with sparfloxacin, ciprofloxacin, clarithromycin, erythromycin and rifampicin against 181 
strains of Legionella pneurnophila, nine strains of L. rnicdadei, 10 strains of L. durnoffii, seven strains of L. longbeachae 
and seven other Legionella strains. 
Methods: MlCs were determined by standard agar dilution using buffered yeast extract (BYE) agar. PAE and human 
monocyte activity were determined by standard culture techniques. 
Results: Grepafloxacin, sparfloxacin and rifampicin were the most active agents against L. pneurnophila (MICgo 50.016 
mg/L for most strains tested). Grepafloxacin was more active than erythromycin against L. durnoffii and L. longbeachae 
and more active than both erythromycin and clarithromycin against L. rnicdadei and isolates of other Legionella spp. 
The PAE of grepafloxacin against erythromycin-susceptible L. pneurnophila (2.62 h) was higher than that of sparfloxacin 
(0.88 h), erythromycin (0.93 hours) and clarithromycin (0.72 h). Against erythromycin-resistant L. pneurnophila, the 
PAE of grepafloxacin (4.18 h) was higher than those of all the other antibiotics tested. Grepafloxacin, sparfloxacin, 
ciprofloxacin and clarithromycin inhibited the growth of all L. pneurnophila strains and other erythromycin-resistant 
Legionella spp. in  human monocytes. However, only grepafloxacin and ciprofloxacin prevented regrowth or killed 
L. pneurnophila after removal of extracellular antibiotic. 
Conclusions: Grepafloxacin showed effective antibacterial activity against the Legionella spp. tested, and has a PAE 
and activity within human monocytes that suggest it may be useful in  the treatment of lower respiratory tract infections 
caused by Legionella spp. 
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Pneumonia caused by Legionella pneumophila can 
be severe and life-threatening. The recognition of 
community-acquired pneumonia (CAP) caused by 
pathogens such as Legionella spp. is increasing, although 
it remains relatively uncommon 111. Although the 
reported frequency of legionella pneumonia often 
varies markedly from study to study, this variation 
can probably be explained by the different ways 
in which the studies are conducted. Thus, a fairly 
recent European study [2] reports a 3% frequency 
of community-acquired legionella pneumonia, while 
another reports that, of all cases of severe CAP 
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requiring patient hospitalization, about 4%) of cases are 
caused by L. pneumophila and other Legionella spp. [3]. 
L. pneumophila is the species most commonly associated 
with legionella pneumonia. 
If it is treated promptly, mortality rates associated 
with community-acquired legionella pneumonia, in 
otherwise healthy individuals, are low (5%). However, 
this mortality rate increases up to 15-30% among 
untreated patients in the same population 1.11. 
Antimicrobial therapy for CAP caused by Legionella 
spp., as for other intracellular pathogens causing atypical 
infections, is dictated by the facultative intracellular 
nature of these bacteria; only agents achieving intra- 
cellular penetration are likely to be effective. Antibiotic 
efficacy is dependent on the ability to penetrate 
phagocytes and on the suitability of the intracellular 
environment for expression of drug activity 151. 
Consequently, serum drug concentrations or serum 
bactericidal activities may be relatively unimportant, 
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and susceptibility testing using intracellular models may 
be used to augment standard MIC assays. 
Erythromycin, alone or in combination with agents 
such as rifampicin, is the usual treatment of choice for 
legionella pneumonia, though the newer macrolides, 
clarithromycin and azithromycin, are also effective, and 
offer improved bioavailability, drug interaction and 
dose regimen profiles. Azithromycin exhibits similar 
activity to erythromycin against extracellular L. pneumo- 
pkila, but is bactericidal or irreversibly inhibitory 
against the intracellular pathogen, in contrast to the 
solely reversible inhibition seen with erythromycin [6]. 
Azithromycin also demonstrates enhanced efficacy 
compared with clarithromycin [7]. While rifampicin is 
remarkably active against both extra- and intracellular 
Legionella spp., it too is reversibly inhibitory and its use 
as monotherapy is discouraged on the theoretical 
grounds of possible emergence of resistance [4]. In fact, 
the use of rifampicin as sole therapy for legionnaires’ 
disease has not been reported 141. 
The fluoroquinolone antibiotics also exhibit clinical 
efficacy in legionnaires’ disease and, as a class, have the 
greatest activity against L. pneumopkila in experimental 
models [4]. Their excellent activity against intracellular 
L. pneumophila is consistently higher than that obtained 
with erythromycin [4]. Furthermore, in contrast to the 
macrolides (with the possible exception of azithro- 
mycin), they are bactericidal rather than bacteriostatic 
[4]. Ofloxacin, pefloxacin and ciprofloxacin have all 
been used for the treatment of legionnaires’ disease. 
As antimicrobial resistance patterns to respiratory 
pathogens continue to change, there have been increased 
attempts to develop new agents with extended and 
improved spectra of activity, effective against a wide 
range of causative pathogens. This is important in 
relation to the empirical setting in which antibiotics for 
respiratory tract infections are commonly prescribed. 
Grepailoxacin is a new, broad-spectrum fluoroquinolone 
with improved Gram-positive activity over cipro- 
floxacin and potent in vitro activity against many 
Gram-negative and intracellular pathogens [8,9]. In 
addition, levels of grepafloxacin in bronchial mucosa, 
epithelial lining fluid and macrophages have been found 
to be significantly higher than the mean serum 
concentration [lo]. These levels attained at the site of 
respiratory tract infection exceed those reported for 
other fluoroquinolones, and are considerably higher 
than previously reported MIC90 levels for common 
respiratory pathogens. This agent would, therefore, 
appear to be well suited for the treatment of legionella 
infection. Other new fluoroquinolones have potent in 
vitro activity against Legionella, including levofloxacin, 
sparfloxacin, and trovafloxacin [l 1 ,121. These agents 
also penetrate well into respiratory tissues, although the 
concentrations achieved are lower than those observed 
with grepafloxacin [13-151. 
In order to evaluate the potential of grepadoxacin, 
this study set out to compare the MIC, postanti- 
biotic effect (PAE) and human monocyte activity of 
grepafloxacin, spadoxacin, ciprofloxacin, erythromycin, 
clarithromycin and rifampicin against a variety of 
Legionella species. 
MATERIALS AND METHODS 
Susceptibility testing 
Isolates 
Legionella isolates from the human respiratory tract and 
environmental sources were grown to produce pure 
cultures on buffered charcoal yeast extract agar. The 
organisms investigated were L. pneumopkila from eight 
different serogroups (n=181),  L. micdadei (n=9), 
L. dumojii (n=10), L. longbeackae (n=7), and other 
Legionella strains, including one strain each of L. 
oakridgensis, L. feeleii, L. jordanis, L. gormanii, L. 
wadswortkii, L. sainthelensi and L. bozemanii. Multiple 
cultures from the same patient or source were excluded 
unless a change in the organism or antibiogram was 
noted. Identification of organisms was done according 
to standard methodology [16]. 
Antibiotics 
Standard antibiotic reference powders were provided by 
the following sources: grepafloxacin, GlaxoWellcome, 
Greenford, UK; sparfloxacin, Rh8ne-Poulenc Rorer 
Co., MontrCal, Canada; ciprofloxacin, Miles Pharma- 
ceuticals, Etobicoke, Canada; clarithromycin, Abbott 
Laboratories, Chicago, Illinois, USA; rifampicin and 
erythromycin, Sigma, Mississauga, Ontario, Canada. 
MIC determination 
MICs were determined by standard, two-fold agar 
dilution using buffered yeast extract (BYE) agar as 
previously described by Edelstein and Edelstein [6]. 
Endpoints were expressed as the lowest concentrations 
of antibiotic that completely inhibited visible growth. 
The inoculum was prepared overnight by addng pure 
colonies to sterile water to a turbidity of no. 1 
McFarland standard. The inoculum was diluted lo-’, 
and around lo4 CFU were plated onto BYE agar 
containing doubling dilutions of antibiotics fkom 0.004 
to 256 mg/L. Plates were incubated at 35OC for 48 h. 
Pseudomonas aeruginosa ATCC 27853 and L. pneumo- 
phila ATCC 33152 were used as reference strains. 
Determination of PAE 
PAE was determined using the broth technique 
described by Craig 1171. Antibiotics were diluted in 
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sterile water to give a concentration 100-fold higher 
than the test concentration. A 100-pL aliquot of this 
solution was added to 8.9 mL BYE prewarmed to 
37°C. To mimic achievable serum concentrations as 
closely as possible, all strains were exposed to antibiotic 
concentrations four times higher than the MIC. 
Colonies of Lcgionella were inoculated in BYE and 
incubated at 37°C overnight to obtain test cultures in 
the logarithmic phase of growth. A 1-mL aliquot of 
each culture was then added to each antibiotic solution 
and to 9 mL of control medium containing no anti- 
biotic. These dilutions resulted in a final concentration 
of 106-107 CFU/mL. In all cases, a residual antibiotic 
control and a control without antibiotic were included; 
all experiments were conducted in duplicate. 
Tubes containing the antibiotic and test cultures 
were incubated in a shaking water bath at 37°C for 
1 h. Antibiotic was then removed by three consecutive 
centrifugations at l2OOg for 10 min into fresh broth, 
and the tubes were maintained in the water-bath. 
Bacterial counts (CFU/mL) were performed on all 
cultures at time 0, before and after washing, and every 
hour until turbidity developed. Counts were mapped 
on a graph and PAE was calculated using the formula: 
PAE=T-C 
where P t i m e  taken for the count in the test culture 
to increase 1 loglo above the count obtained immediately 
after antibiotic removal, and C= time taken for the 
count in the control culture to increase 1 loglo above 
the count obtained immediately after the same pro- 
cedure in this culture. 
Determination of human monocyte activity 
Human monocyte activity was assayed using the mono- 
nuclear cells described by Honvitz [18]. Heparinized 
blood was prepared by centrifuging at 1100 rev/min 
for 15 min; plasma was removed and replaced with 
phosphate-buffered saline and dextran 2%. The mono- 
nuclear cell fraction was obtained by further centri- 
fugation as previously described [18], separated from 
other cells by adherence on a Petri dish, and kept 
in RPMI 1640 [18] until required. Antibiotics were 
diluted as for PAE assessment, and a 100-pL aliquot was 
added to 2.0 mL RPMI 1640 + serum culture medium 
pre-warmed to 37°C. All strains were exposed to 
antibiotic concentrations twice the MIC. Controls with- 
out antibiotic ? human monocytes were included and 
all assays were done in duplicate. 
RPMI 1640 medium containing 15%) fresh human 
serum (pH 6.85-6.95 a t  37°C) was inoculated with 
2 niL of RPMI 1640 medium containing 5 X  106 
mononuclear cells. Legionella colonies were inoculated 
in BYE and incubated at 37°C overnight to obtain 
test cultures in the logarithmic phase of growth. An 
inoculum of 106-107 CFU/mL of Legionella was then 
added to each of the antibiotic solutions, and to 2.0 mL 
of control medium containing no antibiotic. These 
dilutions resulted in a final concentration of 2.5 x lo4 
CFU/mL. The intracellular location of the Legionella 
strains was confirmed by using Gienisa's stain. 
Cultures were incubated in a shaking water-bath at 
37°C for 1 h. After 48 h, the cultures were washed to 
remove the antibiotic, and cultures were split into two 
groups: one was reincubated with the same antibiotic, 
and the second was incubated without the antibiotic. 
After this time, the cultures were maintained under 
stationary conditions for 4-5 days at 37°C in 5% CO2. 
Bacterial counts (CFU/mL) were performed on all 
cultures at time 0, before and after washing, and every 
day in triplicate. Bacterial counts were then mapped on 
a graph or tabulated. 
Susceptibility testing 
The activity of the study antibiotics against L. pneurno- 
phila serogroups 1-8 is shown in Table 1. Grepafloxacin 
(MICgo 0.008-0.03 mg/L) was more active than 
erythromycin ( M I C ~ O  0.25-1 .O mg/L) and clarithro- 
mycin (MICyn 0.06 mg/L) against the L. pneumopkila 
strains tested, but not as active as rifampicin (MICw 
10.008 nig/L) or spadoxacin (MIC9o 10.00-1-0.016 
mg/L). Grepafloxacin was overall more active than 
ciprofloxacin against L. ptieumophila, with the exception 
of serogroups 2 and 5, for which the MICyos for 
grepafloxacin and ciprofloxacin were the same (0.01 6 
mg/L and 0.03 mg/L, respectively). 
In general, L. pneirmophila serogroups 6-8 were 
more susceptible to grepafloxacin (MICw 0.008 mg/L) 
than were serogroups 1-5 (MICyo 0.016-0.03 mg/L). 
The MIC:)os of the test antibiotics against other 
Legionella species are shown in Table 2. Grepafloxacin 
was more active than erythromycin against L. drimojfii 
and L. longheachae and more active than both erythro- 
mycin and clarithromycin against L. micdadei and 
isolates of other Legionella spp. Compared with cipro- 
floxacin, grepafloxacin was equally active against L. 
micdadei and seven isolates of other Legionella spp. and 
slightly less active against L. dumojii and L. loqbeaclzae. 
PAE assessment 
The PAE values of test antibiotics obtained with 
erythromycin-susceptible or -resistant L. ptieiimophila 
are shown in Table 3.  The PAE of grepafloxacin (3.62 
h) against erythromycin-susceptible L. pneumopkila was 
longer than those of sparfloxacin (0.88 h), erythro- 
mycin (0.93 h) and clarithromycin (0.717 h). Moreover, 
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Table 1 Susceptibility of Legionella pneumophila serogroups 1-8 to the study antibiotics 
MIC (mg/L) 
Microorganism Antibiotic Range 50% 90% 
L. pneumophila Grepafloxacin 
serogroup 1 (71 isolates) Sparfloxacin 
Ciprofloxacin 
Clarithromycin 
Erythromycin 
Rifampicin 
L. pneumophila 
serogroup 2 (1 7 isolates) 
L. pneumophila 
serogroup 3 (14 isolates) 
L. pneumophila 
serogroup 4 (21 isolates) 
L. pneumophila 
serogroup 5 (15 isolates) 
L. pneumophila 
serogroup 6 (39 isolates) 
L. pneumaphiln 
serogroup 7 (2 isolates) 
L. pneumophila 
serogroup 8 (2 isolates) 
Grepafloxacin 
Sparfloxacin 
Ciprofloxacin 
Clarithromycin 
Erythromycin 
Rifampicin 
Grepafloxacin 
Sparfloxacin 
Ciprofloxacin 
Clarithromycin 
Erythromycin 
Rifampicin 
Grepafloxacin 
Sparfloxacin 
Ciprofloxacin 
Clarithromycin 
Erythromycin 
Rifampicin 
Grepafloxacin 
Sparfloxacin 
Ciprofloxacin 
Clarithromycin 
Erythromycin 
Rifampicin 
Grepafloxacin 
Sparfloxacin 
Ciprofloxacin 
Clarithromycin 
Erythromycin 
Kifampicin 
Grepafloxacin 
Sparfloxacin 
Ciprofloxacin 
Clarithrornycin 
Erythromycin 
Rifampicin 
Grepafloxacin 
Sparfloxacin 
Ciprofloxacin 
Clarithromycin 
Erythromycin 
Rifampicin 
50.004-0.06 
0.01-0.25 
50.004-0.06 
5 0.004-0.12 
0.06-1.0 
50.004-0.008 
5 0.004-0.03 
50.004" 
50.004-0.03 
10.004-0.06 
0.008-0.5 
50.004" 
SO.004-0.016 
50.004-0.03 
0.12-0.5 
5 0.004-0.008 
0.03-0.06 
50.004a 
50.004-0.016 
50.004-0.008 
0.03-0.12 
0.03-0.06 
50.004-0.008 
0.06-0.5 
10.004-0.06 
50.004-0.06 
0.0164.06 
0.016-0.06 
0.06-1.0 
50.004a 
50.004-0.016 
50.004-0.008 
50.004-0.03 
10.004-0.06 
0.008-0.25 
10.00.19.008 
SO.004-0.008 
50.004" 
0.03a 
0.12-0.5 
0.016-0.06 
50.004" 
O.00€ia 
50.004a 
0.03" 
0.06" 
0.25a 
50.004" 
0.016 
50.004 
0.03 
0.06 
0.25 
50.004 
0.008 
50.004 
0.016 
0.03 
0.25 
50.004 
0.008 
50.004 
0.03 
0.03 
0.25 
50.004 
0.008 
50.004 
0.03 
0.06 
0.5 
50.004 
0.016 
S0.004 
0.03 
0.25 
50.004 
0.03 
0.008 
50.004 
0.03 
0.016 
0.12 
50.004 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.016 
50.004 
0.03 
0.06 
1.0 
0.008 
0.016 
50.004 
0.016 
0.06 
0.25 
50.004 
0.016 
50.004 
0.03 
0.06 
0.5 
50.004 
0.016 
50.004 
0.06 
0.06 
0.5 
50.004 
0.03 
0.016 
0.03 
0.06 
0.5 
50.004 
0.008 
50.004 
0.03 
0.06 
0.25 
50.004 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
aThe minimum concentration tested was 0.004 mg/mL.. 
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Table 2 Susceptibility of other L q i o ~ e l l u  species to the study antibiotics 
MIC (mg/L) 
Microorganism Antibiotic Kangc SO?.;, 90% 
L. dctmofii 
(10 isolates) 
L. mirdadei 
(nine isolates) 
L. longbeachue 
(seven isolates) 
Other Lqiowellu species 
(seven isolates)a 
Grepafloxacin 
Spadoxacin 
Ciprofloxacin 
Clarithromycin 
Erythromycin 
Rifampicin 
Grepafloxacin 
Spadoxacin 
Ciprofloxacin 
Clarithroniycin 
Erythromycin 
Rifampicin 
Grepafloxacin 
Spartloxacin 
Ciprofloxacin 
Clarithromycin 
Erythroiiiyciii 
Rifampicin 
Grepafloxacin 
Spartloxacin 
Ciprofloxacin 
Clarithroniycin 
Erythromycin 
Rifampicin 
0.06b 
0.008-U.0 16 
0.01 6-0.03 
0.15-0.5 
0.03-0.06 
50.004-0.03 
50.004-0.016 
50.004” 
0.016-0.03 
0.03-0.12 
0.5-1.0 
50.004-0.008 
50.004-0.06 
50.004-0.03 
so.004-0.03 
0.008-0.06 
0.008-0.5 
50.004-0.06 
50.004-0.03 
5 0.004-0.016 
50.004-0.03 
5 0.00M.  12 
0.016-1 .o 
50.0044.008 
’One strain each of L. oakvidgensis, L. feefeii, L. jordanir, L. gormanii, L. umhuorthii,  L. sainthelensi and L. bozemunii 
“The minimum concentration tested was 0.004 nig/mL. 
the PAE of grepafloxacin (4.18 h) against erythromycin- 
resistant L. pnrumophila was superior to that of all the 
other test antibiotics. 
For other Legionella spp. tested, the mean PAE of 
grepafloxacin against erythromycin-susceptible strains 
was higher than that of clarithromycin, while for 
erythroniycin-resistant strains, grepafloxacin’s mean 
PAE was higher than those of both ciprofloxacin and 
clarithromycin (Table 3). The mean PAE of erythro- 
mycin against species other than L. pneumophila was 
longer for erythromycin-susceptible isolates (2.06 h) 
than for erythromycin-resistant isolates (0.44 h). How- 
ever, no measurable PAE was observed with erythro- 
mycin against erythromycin-susceptible or -resistant 
L. micdadei and L. drrmo&i or against erythromycin- 
resistant L. bozemanii and L. u u d r u w t h i i  (data not shown). 
Human monocyte activity 
Grepafloxacin, sparfloxacin and ciprofloxacin were 
bactericidal against both erythromycin-susceptible and 
-resistant intracellular L. pnertmophila (Table 4).  Bacteri- 
cidal activity was defined as a >3 log reduction in viable 
cell numbers (99.9% kill), and this effect was also seen 
with other Legionella spp. (Table 5). The bactericidal 
activity of grepafloxacin and ciprofloxacin against 
intracellular L. pneumoplzila continued even after their 
removal from the medium (Table 6). 
DISCUSSION 
The organisms tested in this study were: L. pnenmophila 
(serogroups 1-8) (181), L. durnoffii (lo), L. micdadei 
(nine) and L. longbenchae (seven). Overall, the results 
confirm the findings of other studies [9,19]. The MIC 
data obtained in this study indicate that grepafloxacin 
is highly active against most Legionella spp. Grepa- 
floxacin’s activity against L. pneumophila serogroup 1 
(MIC9o 0.01 6 mg/L) was particularly interesting, as this 
serogroup demonstrated the least susceptibility to 
erythromycin (MICso 1.0 mg/L), and WAS the most 
common strain isolated from patients with nosocomial 
or community-acquired respiratory tract infections. As 
anticipated, rifampicin was also found to be very active 
against the Legionella spp. tested, and was the most 
highly active agent against L. pneumophila. 
Grepafloxacin’s activity against L. yneirmophila was 
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Table 3 Mean PAE of test antibiotics against erythromycin-resistant and -susceptible strains of Legionella spp." 
Mean PAE (h) 
Microorganism Grepafloxacin Sparfloxacin Ciprofloxacin Clarithromycin Erythromycin Rifampicin 
Erythromycin-resistant strains 
L. pneumophila 
Other Lpgionella ~ p p . ~  
(n=7) 4.18 f 3 0.68 f 1 2.86 f 2 1.90 f 1 0.90 f 1 0.93 f 4 
(n=8) 2.42 + 3 0.72 f 2 2.13 f 1 1.60 f 2 0.44 t 1 5.60 f 3 
Erythromycin-susceptible strains 
L. pneumophila 
Other Legionella spp.' 
(n=15) 2.62 f 3 0.88 f 6 3.61 f 2 0.72 f 2 0.93 f 1 2.86 t 5 
(n=13) 1.18 It 2 1.10 f 1 1.86 f 2 0.98 f 2 2.06 k 2 3.09 t 4 
"Means are given f SD. 
bL. micdadei (n=l),  L. dumogii (n=3), L. bozemunii (n=l), L. wudsworthii (n=l), L. jordunis (n=l), L. longbeuchae (n=2). 
'L. micdadei (n=4), L. dumogii (n=5), L. bozemunii (n=l), L. gormanii (n=l), L. jordanis ( ~ 1 ) .  L. longbeuchae (n=l) 
Antibiotics were used at concentrations four times the MIC. 
Table 4 Effect of test antibiotics o n  intracellular multiplication of erythromycin-resistant and -susceptible strains of Legionella 
pneumophila 
CFU/mI, (loglo) 
Strain Day Grepafloxicin 
Erythromycin-resistant strains 
No. 5 0 3.2 (4)" 
2 3.4 (2) 
4 2.1 (2) 
6 2.2 (4) 
7 3.4 (5) 
5 1.6 (3) 
Sparfloxacin Ciprofloxacin Clarithromycin Erythromycin Wampicin 
3.2 (4) 3.2 (4) 3.2 (4) 3.2 (4) 3.2 (4) 
4.2 (2) 8.4 (1) 8.6 (3) 9.4 (3) 9.6 (3) 
3.6 (2) 3.8 (3) 4.2 (3) 4.8 (4) 4.0 (4) 
5.5 (4) 5.1 (5) 1.0 (3) 6.2 (5) 4.2 (5) 
6.4 (5) 7.5 (5) 2.6 (5) 7.0 (6) 4.1 (6) 
9.2 (6) 2.0 (6) 3.1 (6) 1.8 (7) 2.3 (7) 
No. 24 0 3.9 (4) 3.9 (4) 3.9 (4) 3.9 (4) 3.9 (4) 3.9 (4) 
2 2.6 (2) 8.8 (2) 8.4 (1) 6.3 (3) 1.4 (4) 8.3 (3) 
4 1.2 (2) 7.3 (2) 6.1 (3) 1.1 (3) 4.2 (4) 6.1 (4) 
5 2.2 (3) 6.5 (4) 7.5 (5) 4.2 (4) 5.9 (5) 7.1 (5) 
6 3.5 (4) 7.1 (5) 7.9 (5) 7.6 (5) 6.8 (6) 5.2 (6) 
7 4.1 (5) 7.7 (6) 3.1 (6) 2.6 (6) 2.1 (7) 4.6 (7) 
Erythromycin-susceptible strains 
No. 121 0 3.2 (4) 3.2 (4) 3.2 (4) 3.2 (4) 3.2 (4) 3.2 (4) 
2 5.1 (2) 4.8 (3) 9.9 (2) 2.5 (3) 5.5 (3) 9.1 (3) 
4 8.7 (3) 3.2 (3) 5.1 (3) 1.1 (3) 9.0 (4) 9.6 (4) 
5 3.9 (4) 6.1 (4) 6.0 (5) 8.2 (4) 3.2 (5) 5.0 (5) 
6 4.6 (5) 5.9 (5) 9.8 (5) 2.3 (5) 7.2 (6) 6.3 (6) 
7 6.4 (6) 9.8 (6) 3.9 (6) 8.1 (6) 3.0 (7) 3.8 (7) 
No. 123 0 3.6 (4) 3.6 (4) 3.6 (4) 3.6 (4) 3.6 (4) 3.6 (4) 
2 6.7 (2) 3.1 (3) 1.9 (3) 2.0 (3) 5.7 (3) 3.1 (4) 
4 5.8 (3) 7.0 (4) 9.8 (2) 1.2 (3) 7.1 (4) 4.6 (4) 
5 4.8 (4) 9.5 (4) 6.4 (4) 2.6 (4) 6.3 (5) 7.1 (5) 
6 5.4 (5) 6.1 (5) 8.6 (5) 4.6 (5) 5.1 (6) 2.7 (6) 
7 6.2 (6) 8.6 (6) 4.1 (6) 8.2 (6) 9.9 (6) 3.9 (6) 
Antibiotics were used at concentrations twice the MIC. 
"Example: 3.2 (4) means 3.2 CFU/ml by loglo to 4. See also Tables 5 and 6 
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Table 5 Effect of test antibiotics on intracellular multiplication of other erythromycin-resistant Legionella spp. 
C F U / d  floeid 
Strain Day Grepafloxicin Spadoxacin Ciprofloxacin Clarithromycin Erythromycin Rifampicin 
No. 164 (L. micdadei) 0 6.3 (4) 6.3 (4) 6.3 (4) 6.3 (4) 6.3 (4) 6.3 (4) 
2 4.2 (2) 4.2 (3) 5.2 (2) 1.8 (3) 5.4 (4) 9.1 (2) 
4 1.8 (2) 2.6 (3) 1.3 (2) 1.1 (3) 8.8 (4) 5.6 (2) 
5 1.1 (4) 9.6 (4) 8.5 (4) 1.9 (4) 9.2 (5) 9.6 (3) 
6 4.3 (5) 7.3 (5) 9.1 (5) 8.3 (5) 9.6 (6) 7.6 (4) 
7 6.8 (6) 9.1 (6) 5.3 (6) 7.9 (6) 9.8 (7) 9.2 (5) 
No. 186 (L.  longbeachae) 0 2.7 (4) 2.7 (4) 2.7 (4) 2.7 (4) 2.7 (4) 2.7 (4) 
4 1.2 (2) 6.8 (3) 2.4 (2) 1.6 (3) 7.1 (4) 1.3 (2) 
5 1.0 (3) 5.9 (4) 5.7 (3) 2.8 (4) 7.8 (5) 1.9 (3) 
6 7.8 (3) 5.6 (5) 9.3 (3) 3.6 (5) 8.4 (6) 4.6 (4) 
2 4.5 (2) 9.9 (3) 3.8 (2) 2.3 (3) 9.9 (3) 4.5 (2) 
7 2.6 (4) 7.4 (6) 2.1 (4) 9.2 (5) 2.5 (7) 5.5 (5) 
Antibiotics were used at concentrations twice the MIC. 
Table 6 Effect of withdrawing the test antibiotic at 24 h on intracellular multiplication of erythromycin-resistant and 
-susceptible strains of L. pneumophila 
C F U / d  (loglo) 
Strain Day Grepafloxicin Spadoxacin Ciprofloxacin Clarithromycin Erythromycin Rifampicin 
Erythromycin-resistant strains 
No. 5 0 
2 
4 
5 
6 
7 
No. 24 0 
3.2 (4) 
5.8 (2) 
6.5 (2) 
4.2 (3) 
1.6 (4) 
3.2 (5) 
3.9 (4) 
5.8 (2) 
1.8 (3) 
4.6 (6) 
5.9 (6) 
2.1 (5) 
3.2 (4) 
4.8 (2) 
2.7 (5) 
7.9 (6) 
5.8 (2) 
7.5 (5) 
3.9 (4) 
4.4 (2) 
5.7 (2) 
3.8 (5) 
9.1 (5) 
9.9 (6) 
3.2 (4) 
2.8 (2) 
7.2 (3) 
4.2 (5) 
6.2 (5) 
5.7 (2) 
3.9 (4) 
4.1 (2) 
6.7 (3) 
6.3 (5) 
6.7 (6) 
1.5 (6) 
3.2 (4) 
2.6 (3) 
8.6 (4) 
3.6 (4) 
8.6 (6) 
7.9 (5) 
3.9 (4) 
8.5 (3) 
4.1 (4) 
6.3 (6) 
8.6 (6) 
5.9 (5) 
3.2 (4) 3.2 (4) 
3.2 (4) 2.1 (4) 
8.2 (4) 5.9 (4) 
5.9 (5) 4.8 (5) 
8.6 (6) 6.9 (6) 
9.3 (6) 3.2 (7) 
3.9 (4) 3.9 (4) 
9.9 (4) 3.4 (4) 
6.3 (5) 5.5 (4) 
7.7 (6) 9.9 (5) 
9.9 (6) 1.1 (7) 
8.5 (6) 9.1 (6) 
No. 123 
Erythromycin-susceptible strains 
No. 121 0 3.2 (4) 3.2 (4) 3.2 (4) 3.2 (4) 3.2 (4) 3.2 (4) 
2 1.4 (2) 9.9 (2) 1.1 (3) 5.2 (3) 4.5 (4) 1.4 (4) 
4 2.1 (3) 8.5 (3) 6.6 (3) 9.6 (3) 4.1 (4) 4.8 (5) 
6 8.6 (5) 6.8 (5) 1.0 (6) 8.5 (5) 1.2 (7) 7.5 (6) 
7 9.6 (6) 1.1 (7) 1.2 (7) 7.6 (6) 2.3 (7) 4.1 (7) 
5 6.6 (5) 2.1 (4) 7.6 (5) 7.6 (5) 1.2 (6) 7.4 (5) 
0 3.6 (4) 3.6 (4) 3.6 (4) 3.6 (4) 3.6 (4) 3.6 (4) 
4 9.3 (3) 9.8 (4) 2.6 (4) 8.7 (3) 1.0 (5) 7.4 (4) 
7 9.0 (6) 1.2 (7) 8.9 (6) 9.2 (6) 4.3 (7) 9.9 (7) 
2 2.6 (3) 4.4 (3) 1.2 (4) 6.9 (3) 1.1 (4) 6.8 (4) 
5 6.9 (5) 4.8 (5) 7.7 (5) 9.6 (4) 1.9 (6) 7.2 (5) 
6 8.5 (5) 1.0 (6) 1.0 (6) 8.1 (5) 1.0 (7) 6.4 (6) 
Antibiotics were used at concentrations twice the MIC. 
found to be superior to that of the two macrolides was found to be slightly more active than ciprofloxacin, 
evaluated, erythromycin and clarithromycin. This but slightly less active than sparfloxacin, against L. 
activity of fluoroquinolones compared to erythromycin pneurnophila. The clinical efficacy of grepafloxacin 
has been noted in other studies [20,21]. against L. pneurnophila has also been demonstrated in an 
In comparison with the two other fluoroquinolones open, non-comparative study of CAP, which included 
evaluated, ciprofloxacin and sparfloxacin, grepafloxacin 14 patients with L. pneurnophila pneumonia. The results 
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showed that grepafloxacin provided effective, well- 
tolerated treatment in this patient subgroup [22]. 
Grepafloxacin demonstrated similar activity to the 
other study antibiotics against the other Legionella spp. 
tested. O f  all the other species tested, L. dumojii and 
L. lotgbearhae were the most resistant to grepafloxacin 
and clarithromycin (MIC90 0.06 mg/L). Erythromycin 
was even less active against these species. No difference 
in grepafloxacin or erythromycin susceptibility was 
noted between isolates obtained from clinical and 
environmental sources. 
PAE is the persistent suppression of bacterial 
growth after short exposure to an antibiotic. As 
L. pnertmophila is a facultative, intracellular bacterium 
which multiplies within phagocytic cells, both PAE 
and bactericidaVbacteriostatic activity may be expected 
to have a relationship with antimicrobial dosing 
regimens. The bactericidal effect and relatively long 
PAE of grepafloxacin against intracellular L. pneumo- 
phila recorded in this study (for both erythromycin- 
sensitive and -resistant strains) combined with its known 
persistently high tissue concentrations [lo] suggest that 
these factors may be of clinical relevance for this agent. 
Considering what is already known about grepa- 
floxacin’s activity against the main respiratory pathogens, 
and the results of this study against Legionella spp., the 
agent appears to offer an excellent therapeutic option 
in the empirical treatment of patients with CAP, 
including that caused by Legionella spp. 
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